EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials

Emily C L Wong iD, John K Marshall, Christopher Ma iD, Vipul Jairath, Walter Reinisch iD, Neeraj Narula iD

Inflammatory Bowel Diseases · 01.08.2026 · 32 (8) · 1644-1648

DOI: 10.1093/ibd/izag054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 04.04.2026. Verfasst von Emily C L Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Can…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Janus Kinase Inhibitors. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Older adults with ulcerative colitis (UC) are often undertreated with advanced therapies due to safety concerns. We evaluated whether outcomes differ by age in randomized trials.

Methods

Post hoc analysis of 2841 participants from 13 UC induction trials of biologics and JAK inhibitors compared efficacy (patient-reported outcomes 2 response/remission, clinical remission, endoscopic improvement) and safety between patients ≥60 years of age vs <60 years of age.

Results

Efficacy and safety outcomes were similar across age groups, with minor therapy-specific variation. Hospitalization was numerically higher in older adults.

Conclusions

Advanced therapies show comparable efficacy and safety in UC regardless of age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsJanus Kinase InhibitorsHumansFemaleMiddle AgedRemission InductionMaleAge FactorsAdultRandomized Controlled Trials as TopicAgedTreatment Outcome

Stichwörter der Autor:innen

PRO-2 remissionPRO-2 responseclinical remissioninflammatory bowel diseaseulcerative colitis

Substanzen

Biological ProductsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
  • Division of Gastroenterology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, ON, Canada.
  • Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Emily C L Wong, Christopher Ma, Walter Reinisch, Neeraj Narula

Zitieren

APA

Wong, E. C. L., Marshall, J. K., Ma, C., Jairath, V., Reinisch, W., & Narula, N. (2026). Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials. Inflammatory Bowel Diseases, 32(8), 1644-1648. https://doi.org/10.1093/ibd/izag054

Vancouver

Wong ECL, Marshall JK, Ma C, Jairath V, Reinisch W, Narula N. Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials. Inflammatory Bowel Diseases. 2026;32(8):1644-1648. doi:10.1093/ibd/izag054

BibTeX
@article{Wong2026,
  author = {Wong, Emily C L and Marshall, John K and Ma, Christopher and Jairath, Vipul and Reinisch, Walter and Narula, Neeraj},
  title = {Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {8},
  pages = {1644--1648},
  doi = {10.1093/ibd/izag054}
}
Kostenlos starten →